Faron Pharmaceuticals Ltd: Holding(s) In Company
TURKU, FI / ACCESS Newswire / September 4, 2026 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)
Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS | ||||
1a. Identity of the issuer or the underlying issuer of existing shares: | Faron Pharmaceuticals Oy | |||
1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) | ||||
Non-UK issuer | X | |||
2. Reason for the notification (please mark the appropriate box or boxes with an "X") | ||||
An acquisition or disposal of shares | ||||
An acquisition or disposal of financial instruments | X | |||
An event changing the breakdown of shares outstanding | ||||
Other (please specify): | ||||
3. Details of person subject to the notification obligation | ||||
Name | Pentwater Capital Management LP | |||
City and country of registered office (if applicable) | Naples, United States | |||
4. Full name of shareholder(s) (if different from 3.) | ||||
Name | ||||
City and country of registered office (if applicable) | ||||
5. Date on which the threshold was crossed or reached: | 01/09/2026 | |||
6. Date on which issuer notified (DD/MM/YYYY): | 02/09/2026 | |||
7. Total positions of person(s) subject to the notification obligation | ||||
% of shares outstanding (total of 8. A) | % of shares outstanding through financial instruments | Total of both in % (8.A + 8.B) | Total number of shares outstanding held in issuer | |
Resulting situation on the date on which threshold was crossed or reached | Less than 3% | Less than 3% | ||
Position of previous notification (if | 3.875746% | 3.875746% |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedv | ||||
A: Shares | ||||
Class/type of | Number of shares outstanding | % of shares outstanding | ||
Direct | Indirect | Direct | Indirect | |
SUBTOTAL 8. A |
B 1: Financial Instruments as an entitlement to acquire | ||||
Type of financial instrument | Expiration | Exercise/ | Number shares that may be acquired if the instrument is | % of shares outstanding |
SUBTOTAL 8. B 1 |
B 2: Financial Instruments with similar economic effect | |||||
Type of financial instrument | Expiration | Exercise/ | Physical or cash | Number of shares | % of shares outstanding |
Swap | Cash Settlement | Less than 3% | Less than 3% | ||
SUBTOTAL 8.B.2 | Less than 3% | Less than 3% |
9. Information in relation to the person subject to the notification obligation (please mark the | |||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer | |||
Full chain of controlled undertakings through which the shares and/or the | X | ||
Name | % of shares outstanding if it equals or is higher than the notifiable threshold | % of shares outstanding through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
Matthew Halbower | |||
MCH PWCM Holdings Inc. | |||
Pentwater Capital Management LP | Less than 3% | Less than 3% | |
10. Additional information | |||
Place of completion | Naples |
Date of completion | 02/09/2026 |
SOURCE: Faron Pharmaceuticals
View the original press release on ACCESS Newswire
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
10 Best Blue-Chip Stocks to Buy for the Long Term
This 1-Star Stock Trades at a 94% Premium. Is It Time to Sell?
